Overview

A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced earlier than in current practice.
Phase:
Phase 4
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Mount Sinai Hospital, Canada
Treatments:
Adalimumab
Antirheumatic Agents
Methotrexate